Roche Patente

The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.

A method of testing tightness between a stopper (3) and a plunger (4) in a syringe (1), wherein the stopper (3) has a distal face (31), a proximal face (32) and an internal cavity (33) opening at the distal face (31), and the syringe (1) has a barrel (2) with a hollow interior, an orifice (21) and an opening (22) opposite to the orifice (21), the method comprising: opening the cavity (33) of the stopper (3) to the proximal face (32), setting the stopper (3) through the opening (22) of the barrel (2) into a hollow interior of the barrel (2) such that the distal face (31) of the stopper (3) is directed towards the plunger (4), coupling a gas detector to the opening (22) of the syringe barrel (2), and providing a gas through the orifice (21; 210; 219) of the barrel (2; 20; 29).

The present invention provides a pharmaceutical composition comprising an effective dosage of at least one anti miR-134 oligonucleotide for administration to a mammal suffering from a disease wherein lowering of the activity of miR-134 is beneficial, wherein single administration of the pharmaceutical composition time interval between each administration is at least 50 days and methods using such composition.

The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

Herein is reported a method for separating full and empty recombinant adeno-associated virus particles using an anion exchange chromatography step, wherein the method comprises a sequence of a applying a solution comprising empty and/or full rAAV particles to an anion exchange chromatography material inside a chromatography column, a first isocratic step, a first linear gradient, a second isocratic step and a second linear gradient, wherein the empty recombinant adeno-associated virus particles are eluted during the first linear gradient and the full recombinant adeno-associated virus particles are eluted during the second linear gradient. In certain embodiments, the solution applied in the first isocratic step comprises about 65 mM of the buffer substance, about 10 mM of the elution salt, about 2 mM of the salt and has a pH value of about 9.4. In certain embodiments, the solution applied in the second isocratic step comprises about 65 mM of the buffer substance, about 90 mM of the elution salt, about 2 mM of the salt and has a pH value of about 9.4. In certain embodiments, the buffer substance is N-(1,1-Dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropane sulfonic acid, the elution salt is tetramethyl ammonium chloride, and the salt is magnesium chloride.

The invention relates to novel compounds having the general formula I <img class="EMIRef" id="4a88fbbf-79dd-4ab1-bc05-7669f8350250-ia01" /> wherein R<1>, R<2>, R<3>, R<4>, X<1> and X<2> are as described herein, composition including the compounds and methods of using the compounds.

The invention relates to a method of manufacturing an in vivo analyte sensing device, which is adapted for detecting at least one analyte in a body fluid or tissue and an in vivo analyte sensing device obtainable by said manufacturing method. Further, the present invention relates to a method of manufacturing a sensor base plate and a sensor base plate obtainable by said manufacturing method. The sensor base plate may be used for the manufacture of an in vivo analyte sensing device.

The present invention relates to an anti-CD20 antibody, which is ocrelizumab, for use in methods of treating multiple sclerosis.

The present invention relates to a clinical diagnostic system, a method for determining the presence or level of at least one analyte of interest in a biological sample, a kit and the uses thereof for efficiently and/or robust detection of an analyte of interest.

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Disclosed herein is a cannula system 1 comprising a soft cannula 10 and a cannula unit for holding the soft cannula 10. The cannula unit comprises a compressing unit 20 and a body unit 30, wherein the body unit 30 contains a mounting structure 31 and a cavity 32 for holding a septum. The soft cannula 10 is threaded on the mounting structure 31. Furthermore, the compressing unit circumferentially surrounds the mounting structure 31 and at least parts of the body unit 30. The compressing unit 20 contains an internal material tension for exerting a compression force on the soft cannula and the mounting structure.

A method for determining at least one state of at least one cavity (114) of a transport interface (116) configured for transporting sample tubes (118) is disclosed. The method comprises: i) (166) capturing at least one image of at least a part of the transport interface (116) by using at least one camera (136); ii) (168) categorizing the state of the cavity (114) into at least one category by applying at least one trained model on the image by using at least one processing unit (140), wherein the trained model is being trained on image data of the transport interface (116), wherein the image data comprises a plurality of images of the transport interface (116) with cavities (114) in different states; iii) (170) providing the determined category of at least one cavity (114) via at least one communication interface (164).

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …